Interferons Patents (Class 435/69.51)
  • Patent number: 9845347
    Abstract: A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Hoffman-La Roche Inc.
    Inventor: Christian Schantz
  • Patent number: 9376478
    Abstract: Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 28, 2016
    Assignee: JURIDICAL FOUNDATION, JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Haruo Sugano, Masami Muramatsu, Tadatsugu Taniguchi
  • Patent number: 9114383
    Abstract: The invention provides extraction columns for the purification of an analyte (e.g., a biological macromolecule, such as a peptide, protein or nucleic acid) from a sample solution, as well as methods for making and using such columns. The columns typically include a bed of extraction media positioned in the column between two frits. In some embodiments, the extraction columns employ modified pipette tips as column bodies. In some embodiments, the invention provides methods of storing columns in a wet state.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: August 25, 2015
    Assignee: PhyNexus, Inc.
    Inventors: Douglas T. Gjerde, Ronald Jones, Allen Burge, Christopher P. Hanna, Leon S. Yengoyan
  • Publication number: 20150147780
    Abstract: Disclosed herein are embodiments for a novel method of producing an organic compound, including harvesting at least one organic compound from an organism or cell line genetically engineered with a gene for at least one proton-pump protein.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Eugene Dinescu, Vincent Dinescu
  • Patent number: 9029522
    Abstract: A recombinant fusion interferon for animals. The recombinant fusion interferon comprises an animal interferon and a Fc region of an animal immunoglobulin G (IgG). The animal interferon and the Fc region of the animal immunoglobulin G can be further joined by a linker. A polynucleotide that encodes the recombinant fusion interferon for animals, a method for producing the recombinant fusion interferon, and the use of the recombinant fusion interferon.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: May 12, 2015
    Assignee: SBC Virbac Biotech Co., Ltd.
    Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
  • Publication number: 20150105537
    Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 16, 2015
    Applicant: BIOGENOMICS LIMITED
    Inventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
  • Patent number: 8993266
    Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: March 31, 2015
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
  • Patent number: 8993724
    Abstract: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: March 31, 2015
    Assignee: Ares Trading S.A.
    Inventors: Dina Fischer, Alain Bernard, Paul Ducommun, Mara Rossi
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Publication number: 20150017685
    Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 15, 2015
    Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
  • Patent number: 8932830
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: January 13, 2015
    Assignee: Biogen Idec Hemophilia, Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
  • Publication number: 20140370546
    Abstract: The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 18, 2014
    Inventors: Christopher Landowski, Anne Huuskonen, Juhani Saarinen, Ann Westerholm-Parvinen, Anne Kanerva, Jari Natunen, Anna-Liisa Hänninen, Noora Salovuori, Merja Pentillä, Markku Saloheimo
  • Publication number: 20140356326
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 4, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
  • Patent number: 8901277
    Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: December 2, 2014
    Assignees: Beijing Tri-Prime Genetic Engineering Co., Ltd, Beijing Bio-Tech Development Co., Ltd.
    Inventors: Jinyi Liu, Xiaoxia Niu, Minyi Zhou, Yi Yang, Jianbo Sun, Yongqing Cheng
  • Patent number: 8900827
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: December 2, 2014
    Assignee: Biogen Idec Hemophilia, Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
  • Publication number: 20140308706
    Abstract: A recombinant fusion interferon for animals. The recombinant fusion interferon comprises an animal interferon and a Fc region of an animal immunoglobulin G (IgG). The animal interferon and the Fc region of the animal immunoglobulin G can be further joined by a linker. A polynucleotide that encodes the recombinant fusion interferon for animals, a method for producing the recombinant fusion interferon, and the use of the recombinant fusion interferon.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 16, 2014
    Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
  • Patent number: 8859497
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 14, 2014
    Assignee: Bolder BioTechnology, Inc.
    Inventor: George N. Cox
  • Publication number: 20140255991
    Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.
    Type: Application
    Filed: January 9, 2014
    Publication date: September 11, 2014
    Applicant: California Institute of Technology
    Inventors: David A. Tirrell, Kristi Lynn Kiick
  • Publication number: 20140255345
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 11, 2014
    Applicant: Allozyne, Inc.
    Inventors: Kenneth H. Grabstein, David A. Tirrell
  • Publication number: 20140220631
    Abstract: Disclosed are a method for rapid screening of suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 7, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jung-Hoon SOHN, Eui-Sung CHOI, Jung-Hoon BAE, Eung-Suck LEE, Mi-Kyung SHIN
  • Publication number: 20140220633
    Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second c
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
  • Publication number: 20140186432
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: December 12, 2013
    Publication date: July 3, 2014
    Applicant: MODERNA THERAPEUTICS, INC.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
  • Patent number: 8709757
    Abstract: A process for producing an interferon alpha 5 (IFNa5) protein by expression in an IFNa5 producing Escherichia coli host cell, wherein incorporation of an extra methionine residue in the N-terminal end of the polypeptide chain is minimized as well as the generation of its oxidized species is disclosed. The IFNa5 protein can be purified by an efficient process to render a biologically active IFNa5.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 29, 2014
    Assignee: Digna Biotech, S.L.
    Inventor: Vladas Algirdas Bumelis
  • Publication number: 20140106403
    Abstract: The invention provides a method of increasing product yield per culture in a population of product-secreting cells bound to a scaffold, for example, a microcarrier, at least partially immersed in a culture medium in a bioreactor. The method comprising: semi-harvesting product by removing a volume of the culture medium with a first-secreted product concentration while leaving the scaffold with the bound cells in the bioreactor; re-feeding the cells by adding a fresh culture medium to increase the culture medium in the bioreactor to approximately the original volume; agitating the culture medium to allow the cells to grow and release a second-secreted product concentration; harvesting product by removing the culture medium with the second-secreted product concentration while leaving the scaffold with the bound cells behind. Also disclosed is a method of increasing virus yield per culture in a population of virus-infected cells bound to a microcarrier suspended in a culture medium.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: XCELLEREX, INC.
    Inventors: PATRICK M. GUERTIN, JOSEPH D. CROWELL
  • Publication number: 20140087392
    Abstract: A glycosyl transferase from Chinese hamster and related methods are described.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 27, 2014
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: James W. Meador, III
  • Publication number: 20140058790
    Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.
    Type: Application
    Filed: November 30, 2011
    Publication date: February 27, 2014
    Applicant: AmideBio LLC
    Inventors: Michael H.B. Stowell, Mikhail Plam
  • Publication number: 20140030220
    Abstract: A recombinant fusion interferon for animals. The recombinant fusion interferon comprises an animal interferon and a Fc region of an animal immunoglobulin G (IgG). The animal interferon and the Fc region of the animal immunoglobulin G can be further joined by a linker. A polynucleotide that encodes the recombinant fusion interferon for animals, a method for producing the recombinant fusion interferon, and the use of the recombinant fusion interferon.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Applicant: SBC Virbac Biotech Co., Ltd.
    Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
  • Patent number: 8623348
    Abstract: Disclosed is an interferon-? (IFN-?) fused protein having IFN-? fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-?, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: January 7, 2014
    Assignee: JW Pharmaceutical Corporation
    Inventors: Chan Kyu Lee, Seonyoung Yang, Eun Ju Kang, Kang Ryu, Hyun Soo Lee, Yong Soo Bae
  • Publication number: 20130324593
    Abstract: The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a ?-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a ?-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine.
    Type: Application
    Filed: November 29, 2011
    Publication date: December 5, 2013
    Applicant: LG Life Sciences Ltd
    Inventors: Yeon Chul Kim, Saem Jung, Jun Jung
  • Patent number: 8568706
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: October 29, 2013
    Assignee: Allozyne, Inc.
    Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
  • Publication number: 20130281667
    Abstract: This invention provides a set of methods for modulating protein spatial configuration. First, select the amino-acid codon for encoding the target protein according to host codon usage. Second, choose combinations which can modulate the spatial configuration and construct into different vectors which can transfect a series of hosts. Third, choose the vector promoter by monitoring a combination of base pairs after combining the code sequence of the promoter and the target protein. Finally, choose the appropriate expression host to express the target protein, refold and purify, measure the activity and spatial configuration.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 24, 2013
    Inventor: Guangwen WEI
  • Patent number: 8563692
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: October 22, 2013
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • Publication number: 20130273606
    Abstract: The invention relates to a nucleic acid molecule encoding a multimeric precursor which after transcription is specifically cleaved in vivo to form multiple copies of a protein of interest. The invention further relates to a cell comprising this nucleic acid molecule and a method for producing a protein of interest using this cell.
    Type: Application
    Filed: April 18, 2013
    Publication date: October 17, 2013
    Inventors: Anna Cornelia Hendrika VAN HAUTUM, Arjo Lysander DE BOER, Jan Bastiaan BOUWSTRA, Peter Franciscus Theresius Maria VAN ASTEN
  • Patent number: 8551469
    Abstract: This invention provides a recombinant interferon (rSIFN-co) and its equivalent with changed spatial configuration, high efficacy and low side effects. Therefore, high dose of rSIFN-co may be used. The cytotoxic effect of rSIFN-co is only one-eighth (?) of currently clinically available interferons but its anti-viral effect is approximately five to twenty (5-20) times higher, and when used in vivo it has a broader spectrum of clinical applications and longer biofeedback response. This invention further provides methods of using the recombinant interferon to treat proliferative disorders such as cancer or viral diseases.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: October 8, 2013
    Assignee: Superlab Far East Limited
    Inventor: Guangwen Wei
  • Patent number: 8524660
    Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: September 3, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: KoChung Lin, R. Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
  • Patent number: 8507221
    Abstract: The present invention discloses an improved process for the production of desired recombinant peptides from bacterial cells by using G-CSF as a novel fusion partner for their high level expression in these cells. The invention further provides an expression system comprising the fusion protein wherein the G-CSF is operatively linked to the peptide of interest via an enzymatic or chemical cleavage site which can be used to separate the fusion partner from the said peptide.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: August 13, 2013
    Assignee: Cadila Healthcare Limited
    Inventors: Sanjeev Kumar Mendiretta, Pankaj R. Patel, Sanjay Bandyopadhyay, Vibhor Saraswat, Arun Kumar Singh
  • Publication number: 20130197068
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 1, 2013
    Applicant: The Trustees Of The University Of Pennsylvania
    Inventor: The Trustees Of The University Of Pennsylvania
  • Publication number: 20130171138
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: November 2, 2012
    Publication date: July 4, 2013
    Applicant: Syntonix Pharmaceuticals, Inc.
    Inventor: Syntonix Pharmaceuticals, Inc.
  • Publication number: 20130164783
    Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.
    Type: Application
    Filed: January 7, 2013
    Publication date: June 27, 2013
    Applicant: IMMUNOMEDICS, INC.
    Inventor: IMMUNOMEDICS, INC.
  • Patent number: 8425895
    Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: April 23, 2013
    Assignee: Novagen Holding Corporation
    Inventors: Haitao Wang, Chunsheng Mao, Jizhi Li, Ling Wang, Yong Du, Longbin Liu, Jing Xu, Rui Zhang
  • Patent number: 8426166
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 23, 2013
    Assignee: Prolor Biotech Inc.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 8399219
    Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 19, 2013
    Assignee: Cytomx Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
  • Publication number: 20130053550
    Abstract: Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
    Type: Application
    Filed: November 19, 2010
    Publication date: February 28, 2013
    Applicant: OXYRANE UK LIMITED
    Inventors: Steven Christian Jozef Geysens, Wouter Vervecken
  • Publication number: 20130017574
    Abstract: Optimized signal peptide coding sequences for enhanced expression and secretion of protein from a cell and related compositions and methods are described. The optimized signal peptide coding sequence encodes an mRNA that contains at least one hairpin structure immediately downstream of the initiation codon. Methods for obtaining the optimized signal peptide coding sequences and methods for enhanced expression and secretion of proteins using the optimized signal peptide coding sequences are also described.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 17, 2013
    Applicant: NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY CORP.
    Inventors: Zhuying WANG, Xiaowu LIU
  • Publication number: 20120308482
    Abstract: Cytokine IFN? nucleic acids from the Cynomolgus monkey are useful for expression of IFN? proteins that are functional homologs of human IFN?. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFN?, the generation and testing of IFN? modulators and related activities.
    Type: Application
    Filed: February 16, 2011
    Publication date: December 6, 2012
    Inventors: Chichi Huang, Jarrat Jordan, Jessica Schreiter
  • Publication number: 20120309057
    Abstract: A process for producing an interferon alpha 5 (IFNa5) protein by expression in an IFNa5 producing Escherichia coli host cell, wherein incorporation of an extra methionine residue in the N-terminal end of the polypeptide chain is minimized as well as the generation of its oxidised species is disclosed. The IFNa5 protein can be purified by an efficient process to render a biologically active IFNa5.
    Type: Application
    Filed: January 31, 2011
    Publication date: December 6, 2012
    Applicant: DIGNA BIOTECH, S.L.
    Inventor: Vladas Algirdas Bumelis
  • Publication number: 20120301922
    Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.
    Type: Application
    Filed: July 6, 2012
    Publication date: November 29, 2012
    Inventors: James M. Cregg, Ilya I. Tolstorukov
  • Publication number: 20120288477
    Abstract: The invention relates to variants of consensus interferon protein with improved properties, such as improved anti-viral activity, and use thereof The variants are also easier to renature after denaturant treatment. The invention also relates to the preparation method of the variants consensus interferon.
    Type: Application
    Filed: July 23, 2012
    Publication date: November 15, 2012
    Inventor: Lin Wang
  • Patent number: 8287852
    Abstract: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and, therefore, is useful in preventing and treating viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods for producing recombinant super-compound interferon or its equivalent and various uses of said interferon.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 16, 2012
    Assignee: Superlab Far East Limited
    Inventor: Guangwen Wei
  • Publication number: 20120258494
    Abstract: The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.
    Type: Application
    Filed: November 22, 2010
    Publication date: October 11, 2012
    Applicant: 4-Anitbody AG
    Inventor: Jörn Stitz